Updated on 2026/07/03

写真a

 
OYAMA Yoko
 
Organization
University Hospital, Medical and Dental Sciences Area University Hospital Clinical Facilities Clinical Laboratory Assistant Professor
Title
Assistant Professor
Degree
(2010.3 Kagoshima University)

Research Interests

  • Clinical Laboratory

Research Areas

General internal medicine

Education

  • 1995.4 - 2001.3    Kagoshima University

Research History

  • 2025.7    Kagoshima University   Assistant Professor

  • 2020.4 - 2026.6    Kagoshima University   Medical and Dental Hospital, Medical and Dental Sciences Area Medical and Dental Hospital Clinical Facilities Clinical Laboratory   Assistant Professor

Professional Memberships

  • 2012.9    日本感染症学会

  • 2010.9    日本東洋学会

  • 2009.9    日本臨床検査専門医会

  • 2008.5    日本乳癌学会

  • 2004.3    日本臨床検査医学会

  • 2001.6    日本内科学会

▼display all

Qualification acquired

  • Specialist

  • Authorized medicine

  • Specialist

  • Authorized medicine

  • Authorized medicine

 

Papers

  • Hashinokuchi H, Yamakuchi M, Higashi S, Takenouchi K, Tabaru A, Oyama Y, Fujisaki C, Tanoue K, Okawa M, Namino F, Hashiguchi T .  AMPK/p38 MAPK signaling selectively enhances HIF-induced VEGF-A165 expression under hypoxic and low-glucose conditions in HepG2 cells to promote endothelial cell proliferation and migration. .  BMC cancer26 ( 1 )   2026.5

    　More details

    Language：English  

    DOI： 10.1186/s12885-026-16069-0

    PubMed

  • Higashi S., Yamakuchi M., Hashinokuchi H., Takenouchi K., Tabaru A., Oyama Y., Fujisaki C., Tanoue K., Hashiguchi T. .  Adaptation to acidic conditions that mimic the tumor microenvironment, downregulates miR-193b-3p, and induces EMT via TGFβ2 in A549 cells .  Plos One20 ( 2 February ) e0318811   2025.2

    　More details

    Language：Japanese   Publisher：Plos One  

    The acidic tumor microenvironment plays a critical role in the malignant transformation of cancer cells. One mechanism underlying this transformation involves epithelial-mesenchymal transition (EMT). This is induced by prolonged exposure to acidic conditions. EMT is an essential process in cancer progression, with Transforming Growth Factor Beta (TGF-β) playing a central role in its induction. However, little was known about the factors regulating TGF-β under acidic conditions. This study aimed to elucidate the mechanism of EMT under acidic conditions and identify novel therapeutic targets to inhibit cancer cell migration and metastasis. Focusing on lung cancer, we explored microRNAs associated with EMT that were differentially expressed under acidic conditions in A549 cells and identified miR-193b-3p as a novel candidate. Under acidic conditions, miR-193b-3p expression decreased around days 3–14. Downregulation of miR-193b-3p promoted increased TGFβ2 expression, resulting in EMT changes in A549 cells. Our study suggests that the interaction between miR-193b-3p, TGFβ2, and the acidic tumor microenvironment promotes cancer EMT change. Understanding these interactions may not only enhance our biological comprehension of cancer, but also pave the way for the development of targeted therapies to inhibit cancer metastasis.

    DOI： 10.1371/journal.pone.0318811

    Scopus

    PubMed

  • Okawa M., Yamakuchi M., Bibek A., Takenouchi K., Maywar D.N., Yamada S., Inoue K., Higurashi K., Nakazawa J., Kawahira M., Kodama T., Tanoue K., Oyama Y., Higashi S., Fujisaki C., Hashinokuchi H., Tabaru A., Kanda H., Tachioka S., Imoto Y., Hashiguchi T., Soga Y. .  Plasma and serum concentrations of VEGFA121, but not of VEGF-A165, increase post-bevacizumab administration .  Plos One19 ( 12 December ) e0316035   2024.12

    　More details

    Language：Japanese   Publisher：Plos One  

    Background VEGF-A concentrations were measured in the blood of bevacizumab-treated cancer patients in previous studies, but a consensus has not formed that would develop VEGF-A into a clinical biomarker. Recently, methods to strictly distinguish between the VEGF-A isoforms have been developed but have not yet been applied to cancer patients undergoing bevacizumab treatment. Methods An ELISA that strictly distinguishes between VEGF-A121 and VEGF-A165—the major isoforms of VEGF-A—and a commercially available ELISA for VEGF-A are used to determine the concentration of VEGF-A121, VEGF-A165, and VEGF-A in the blood of 12 patients with advanced colorectal cancer receiving bevacizumab therapy. Results The serum and plasma concentrations of VEGF-A121 increased substantially post-bevacizumab administration; the median increase in serum was 860.8 pg/mL, 95% confidence interval (CI) [468.5, 1128.9], p = 0.0024, and in plasma was 808.6 pg/mL, 95% CI [748.7, 874.0], p = 0.00049. In stark contrast, VEGF-A165 after bevacizumab administration decreased in serum by a medium change of –73.8 pg/mL, 95% CI [–149.4, –10.2], p = 0.0034, with 83.3% of the post-bevacizumab concentrations falling below the high-accuracy threshold of 38 pg/mL; in plasma, all pre and post VEGF-A165 concentrations fell below this threshold. Concentrations of VEGF-A121 and VEGF-A165 in platelets did not change to a statistically significant degree. Adding recombinant VEGF-A121 (and -A165) or bevacizumab to plasma in patients post-bevacizumab administration increased or decreased, respectively, VEGF-A121 and VEGF-A165 levels. The increase in VEGF-A121 in plasma and serum after bevacizumab administration may be due to the dissociation of the complex of tumor-derived VEGF-A121 and bevacizumab when it moves from the stroma into the blood. Conclusions The VEGF-A121 isoform has been uniquely demonstrated as a clear marker of bevacizumab therapy in both plasma and serum, motivating further research on pursuing these isoforms as biomarkers in cancer care.

    DOI： 10.1371/journal.pone.0316035

    Scopus

    PubMed

  • Hamada Y., Tanoue K., Arigami T., Yamakuchi M., Okawa M., Matsushita D., Takenouchi K., Yamada S., Maywar D.N., Nakayama C., Oyama Y., Higashi S., Fujisaki C., Hozaka Y., Kita Y., Hashiguchi T., Ohtsuka T. .  The Vascular Endothelial Growth Factor-A121/Vascular Endothelial Growth Factor-A165 Ratio as a Predictor of the Therapeutic Response to Immune Checkpoint Inhibitors in Gastric Cancer .  Cancers16 ( 23 )   2024.12

    　More details

    Language：Japanese   Publisher：Cancers  

    Background/Objectives: The response rate to immune checkpoint inhibitor (ICI) therapy is limited. Further, there is a need to discover biomarkers to predict therapeutic efficacy. The vascular endothelial growth factor (VEGF) is strongly associated with intra-tumoral immunity; however, its utility as a marker remains unknown. Therefore, our objectives were to examine the isoforms of VEGF and determine whether VEGF levels predict ICI efficacy. Methods: Levels of VEGF isoforms VEGF-A121 and VEGF-A165 were measured in stored serum samples obtained from 30 patients with advanced or recurrent gastric cancer who received nivolumab monotherapy at Kagoshima University Hospital, and the association with prognosis and treatment efficacy was retrospectively analyzed. Results: The serum levels of the total VEGF, VEGF-A121, and VEGF-A165 were not significantly associated with prognosis. However, the ratio of VEGF-A121/VEGF-A165 (VEGF-A121/165) exhibited a statistically significant (p = 0.0088) difference in progression-free survival (PFS) with the low-ratio group having a 67-day prolonged median PFS time. Under univariable analysis, only VEGF-A121/165 values exhibited reduced progression-free survival with statistical significance. When comparing treatment responses in the low (n = 15) and high (n = 15) serum VEGF-A-121/165 groups, RECIST evaluation was 3 to 0 for complete response (CR), 2 to 0 for partial response (PR), 3 to 2 for stable disease (SD), and 3 to 10 for progressive disease (PD). Patients with clinically unsettled PR or SD were classified as non-CR/non-PD (4 vs. 3), with a disease control rate of 80% vs. 33%. Conclusions: The serum VEGF-A121/165 ratio may represent a new, easily measured biomarker for predicting the therapeutic response to ICIs.

    DOI： 10.3390/cancers16233958

    Scopus

    PubMed

  • 大山 宗士, 大山 陽子, 高城 千彰, 清水 健 .  葉状腫瘍と鑑別が困難であった乳腺紡錘細胞癌の1例 .  乳癌の臨床39 ( 3 ) 285 - 290   2024.6

    　More details

    Language：Japanese   Publisher：(株)篠原出版新社  

    患者は62歳,女性.右乳房のしこりを主訴に当院を受診.画像検査を行い,右乳房下外側に1.7cmの腫瘤を認めた.細胞診では上皮性と非上皮性由来の異型細胞を少数認め,針生検では境界悪性を否定できない間質細胞の異形成を伴う葉状腫瘍と診断された.摘出術を行い,最終病理検査にて乳腺紡錘細胞癌と診断された.PET-CT検査を追加し,遠隔転移を疑う異常集積は認めなかった.追加の治療として乳房全切除術および腋窩リンパ節郭清術を行い,最終病理では残存病変およびリンパ節への転移はなく,術後1年経った現在まで再発は認めていない.乳腺紡錘細胞癌はまれな疾患であり,針生検による少量の組織検体では診断が困難な場合もある.今回,葉状腫瘍と鑑別が困難であった紡錘細胞癌の1例を経験したので文献的考察を加えて報告する.(著者抄録)

  • 大山 宗士, 大山 陽子, 高城 千彰, 清水 健 .  針生検で葉状腫瘍が疑われ手術標本にて紡錘細胞癌と診断された1例 .  日本乳癌学会総会プログラム抄録集31回   244 - 244   2023.6

    　More details

    Language：Japanese   Publisher：(一社)日本乳癌学会  

  • Yamakuchi M., Okawa M., Takenouchi K., Bibek A., Yamada S., Inoue K., Higurashi K., Tabaru A., Tanoue K., Oyama Y., Higashi S., Fujisaki C., Kanda H., Terasaki H., Sakamoto T., Soga Y., Hashiguchi T. .  VEGF-A165 is the predominant VEGF-A isoform in platelets, while VEGF-A121 is abundant in serum and plasma from healthy individuals .  Plos One18 ( 4 April ) e0284131   2023.4

    　More details

    Language：Japanese   Publisher：Plos One  

    Vascular endothelial growth factor A (VEGF-A) plays pivotal roles in regulating tumor angiogenesis as well as physiological vascular function. The major VEGF-A isoforms, VEGFA121 and VEGF-A165, in serum, plasma, and platelets have not been exactly evaluated due to the lack of the appropriate assay system. Antibodies against human VEGF-A121 and VEGF-A165 (hVEGF-A121 and hVEGF-A165) were successfully produced and Enzyme-Linked ImmunoSorbent Assay (ELISA) for hVEGF-A121 and hVEGF-A165 were separately created by these monoclonal antibodies. The measurement of recombinant hVEGF-A121 and hVEGF-A165 by the created ELISA showed no cross-reaction between hVEGF-A121 and hVEGF-A165 in conditioned media from HEK293 cells transfected with either hVEGFA121 or hVEGF-A165 expression vector. The levels of VEGF-A121 and VEGF-A165 in serum, plasma, and platelets from 59 healthy volunteers proved that VEGF-A121 level was higher than VEGF-A165 in both plasma and serum in all the cases. VEGF-A121 or VEGFA165 in serum represented higher level than that in plasma. In contrast, the level of VEGFA165 was higher than VEGF-A121 in platelets. The newly developed ELISAs for hVEGFA121 and hVEGF-A165 revealed different ratios of VEGF isoforms in serum, plasma, and platelets. Measuring these isoforms in combination provides useful information as biomarkers for diseases involving VEGF-A121 and VEGF-A165. Copyright:

    DOI： 10.1371/journal.pone.0284131

    Scopus

    PubMed

  • Mukaihara K., Yamakuchi M., Kanda H., Shigehisa Y., Arata K., Matsumoto K., Takenouchi K., Oyama Y., Koriyama T., Hashiguchi T., Imoto Y. .  Evaluation of VEGF-A in platelet and microRNA-126 in serum after coronary artery bypass grafting .  Heart and Vessels36 ( 11 ) 1635 - 1645   2021.11

    　More details

    Language：Japanese   Publisher：Heart and Vessels  

    Platelet functions are thought to contribute to clinical outcomes after heart surgery. This study was conducted to assess the pivotal roles of vascular endothelial growth factor-A (VEGF-A) and microRNA-126 (miR-126) during coronary artery bypass grafting (CABG). Whole blood was collected for platelet isolation from 67 patients who underwent CABG surgery between July 2013 and March 2014. VEGF-A and miR-126 levels in serum, plasma, and platelets were measured at various time points and compared with clinical characteristics. The platelet count was decreased at 3 days after CABG. This dynamic change in platelet count was larger after conventional coronary artery bypass (CCAB) than off-pump coronary artery bypass (OPCAB). VEGF-A in the same number of platelets (IP-VEGF-A) was increased at 3 days after CABG, followed by an increase of VEGF-A in serum (S-VEGF-A) at 7 days after surgery. The miR-126-3p level in serum (S-miR-126-3p) increased rapidly after CABG and then decreased below preoperative levels. The IP-VEGF-A level on day 7 after CABG in patients with peripheral artery disease (PAD), who suffered from endothelial dysfunction, was higher compared with patients without PAD. Conversely, S-miR-126-3p on day 7 after surgery was lower in patients with PAD than in patients without PAD. Low levels of S-miR-126-3p due to endothelial dysfunction may lead to high IP-VEGF-A, which is closely related to complications after CABG.

    DOI： 10.1007/s00380-021-01855-6

    Scopus

    PubMed

  • Mukaihara Kosuke, Yamakuchi Munekazu, Kanda Hideaki, Shigehisa Yoshiya, Arata Kenichi, Matsumoto Kazuhisa, Takenouchi Kazunori, Oyama Yoko, Koriyama Toyoyasu, Hashiguchi Teruto, Imoto Yutaka .  冠動脈バイパス術後の血小板内VEGF-Aと血清中マイクロRNA-126の評価(Evaluation of VEGF-A in platelet and microRNA-126 in serum after coronary artery bypass grafting) .  Heart and Vessels36 ( 11 ) 1635 - 1645   2021.11

    　More details

    Language：English   Publisher：シュプリンガー・ジャパン(株)  

    冠動脈バイパス術(CABG)の治療期間を通じ、血管内皮細胞増殖因子A(VEGF-A)とマイクロRNA(miR)-126が示す役割を評価した。2013年7月～2014年3月に当大学病院を含む2施設でCABGを施行した患者67名(男性率95%、平均66±3歳)から全血を採取して解析に用いた。CABG施行の3日後には血小板数が減少していたが、こうした動的変化はオフポンプCABGを受けた症例よりも従来法でのCABG例の方がより大きく生じていた。同一数の血小板に含まれるVEGF-AのレベルはCABGの3日後に上昇し、血清中のVEGF-Aレベルは7日後に上昇した。血清中のmiR-126-3pのレベルはCABG施行後、急速に上昇し、次いで施行前の水準を下回るまでに低下した。CABGの7日後の時点では、末梢動脈疾患(PAD)であった患者群(全集団の12%)での血小板内VEGF-Aレベルは、PAD非罹患の群に比べ上昇していた。逆にCABGから7日後の血清中miR-126-3pレベルは、非PAD群よりもPAD群の方が低かった。こうした結果から、PADでみられる内皮機能障害に起因してmiR-126-3pの血清中レベルは低下し、そのため血小板内VEGF-Aレベルが上昇するという機序が存在し、これがCABG後の合併症と密接に関係していると考えられた。

  • Kanda H., Yamakuchi M., Matsumoto K., Mukaihara K., Shigehisa Y., Tachioka S., Okawa M., Takenouchi K., Oyama Y., Hashiguchi T., Imoto Y. .  Dynamic changes in platelets caused by shear stress in aortic valve stenosis .  Clinical Hemorheology and Microcirculation77 ( 1 ) 71 - 81   2021

    　More details

    Language：Japanese   Publisher：Clinical Hemorheology and Microcirculation  

    BACKGROUND AND OBJECTIVE: Turbulent blood flow in patients with aortic valve stenosis (AS) results in morphological and functional changes in platelets and coagulation factors. The aim of this study is to determine how shear stress affects platelets and coagulation factors. METHODS: We retrospectively evaluated data from 78 patients who underwent AVR to treat AS between March 2008 and July 2017 at Kagoshima University Hospital. RESULTS: Platelet (PLT) count obviously decreased at three days after AVR, and increased above preoperative levels at the time of discharge. In contrast, platelet distribution width (PDW), mean platelet volume (MPV), and platelet large cell ratio (P-LCR) increased three days after AVR, then decreased to below preoperative levels. No differences were evident between groups with higher (HPPG > 100 mmHg) and lower (LPPG < 100 mmHg) peak pressure gradients (PPG) before AVR, whereas PLT count, PDW, MPV and P-LCR improved more in the HPPG group. Plateletcrit (PCT), which represents the total volume of platelets, increased after AVR due to decreased shear stress. High increasing rate of PCT was associated with lower PLT count, higher PDW and lower fibrinogen. CONCLUSION: Shear stress affects PLT count, PDW, and fibrinogen in patients with AS.

    DOI： 10.3233/CH-200928

    Scopus

    PubMed

  • Sarikaphuti A, Nararatwanchai T, Hashiguchi T, Ito T, Thaworanunta S, Kikuchi K, Oyama Y, Maruyama I, Tancharoen S. .  Preventive effects of Morus alba L. anthocyanins on diabetes in Zucker diabetic fatty rats. .  Exp Ther Med.6 ( 3 ) 689 - 695   2013.9Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Kikuchi K, Kawahara KI, Uchikado H, Miyagi N, Kuramoto T, Miyagi T, Morimoto Y, Ito T, Tancharoen S, Miura N, Takenouchi K, Oyama Y, Shrestha B, Matsuda F, Yoshida Y, Arimura S, Mera K, Tada KI, Yoshinaga N, Maenosono R, Ohno Y, Hashiguchi T, Maruyama I, Shigemori M. .  Potential of edaravone for neuroprotection in neurologic diseases that do not involve cerebral infarction. .  Exp Ther Med2 ( 5 ) 771 - 775   2011.6Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Meng X, Kawahara KI, Miyanohara H, Yoshimoto Y, Yoshinaga K, Noma S, Kikuchi K, Morimoto Y, Ito T, Oyama Y, Yoshinaga N, Shrestha B, Chandan B, Mera K, Tada KI, Miura N, Ono Y, Takenouchi K, Maenosono R, Nagasato T, Hashiguchi T, Maruyama I. .  1,5-Anhydro-D-fructose: A natural antibiotic that inhibits the growth of gram-positive bacteria and microbial biofilm formation to prevent nosocomial infection. .  Exp Ther Med2 ( 4 ) 625 - 628   2011.4Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Kikuchi K, Kawahara KI, Miyagi N, Uchikado H, Kuramoto T, Morimoto Y, Tancharoen S, Miura N, Takenouchi K, Oyama Y, Shrestha B, Matsuda F, Yoshida Y, Arimura S, Mera K, Tada KI, Yoshinaga N, Maenosono R, Ohno Y, Hashiguchi T, Maruyama I, Shigemori M. .  Edaravone: A new therapeutic approach for the treatment of acute stroke. .  Med Hypotheses75 ( 6 ) 583 - 585   2010.8Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Shrestha B, Hashiguchi T, Ito T, Miura N, Takenouchi K, Oyama Y, Kawahara K, Tancharoen S, Ki-I Y, Arimura N, Yoshinaga N, Noma S, Shrestha C, Nitanda T, Kitajima S, Arimura K, Sato M, Sakamoto T, Maruyama I. .  B cell-derived vascular endothelial growth factor A promotes lymphangiogenesis and high endothelial venule expansion in lymph nodes. .  J Immunol. 184 ( 9 ) 4819 - 4826   2010.1Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Oyama Y, Hashiguchi T, Taniguchi N, Tancharoen S, Uchimura T, Biswas KK, Kawahara K, Nitanda T, Umekita Y, Lotz M, Maruyama I. .  High-mobility group box-1 protein promotes granulomatous nephritis in adenine-induced nephropathy. .  Lab Invest.90 ( 6 ) 853 - 866   2010.1Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Saiwichai T, Sangalangkarn V, Kawahara K, Oyama Y, Chaichalotornkul S, Narkpinit S, Harnyuttanakorn P, Singhasivanon P, Maruyama I, Tancharoen S. .  Green tea extract supplement inhibition of HMGB1 release in rats exposed to cigarette smoke. .  Southeast Asian J Trop Med Public Health41 ( 1 ) 250 - 258   2010.1Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Kikuchi K, Kawahara K, Tancharoen S, Matusda F, Morimoto Y, Ito T, Biswas KK, Takenouchi K, Miura N, Oyama Y, Nawa Y, Arimura N, Iwata M, Tajima Y, Kuramoto T, Nakayama K, Shigemori M, Yoshida Y, Hashiguchi T, Maruyama I. .  The free radical scavenger edaravone rescues rats from cerebral infarction by attenuating the release of high-mobility group box-1 in neuronal cells. .  J Pharmacol Exp Ther. 329 ( 3 ) 865 - 874   2009.1Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Kikuchi K, Tancharoen S, Matsuda F, Biswas KK, Ito T, Morimoto Y, Oyama Y, Takenouchi K, Miura N, Arimura N, Nawa Y, Meng X, Shrestha B, Arimura S, Iwata M, Mera K, Sameshima H, Ohno Y, Maenosono R, Tajima Y, Uchikado H, Kuramoto T, Nakayama K, Shigemori M, Yoshida Y, Hashiguchi T, Maruyama I, Kawahara K. .  Edaravone attenuates cerebral ischemic injury by suppressing aquaporin-4. .  Biochem Biophys Res Commun.390 ( 4 ) 1121 - 1125   2009.1Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Kikuchi K, Kawahara K, Biswas KK, Ito T, Tancharoen S, Morimoto Y, Matsuda F, Oyama Y, Takenouchi K, Miura N, Arimura N, Nawa Y, Meng X, Shrestha B, Arimura S, Iwata M, Mera K, Sameshima H, Ohno Y, Maenosono R, Yoshida Y, Tajima Y, Uchikado H, Kuramoto T, Nakayama K, Shigemori M, Hashiguchi T, Maruyama I. .  Minocycline attenuates both OGD-induced HMGB1 release and HMGB1-induced cell death in ischemic neuronal injury in PC12 cells. .  Biochem Biophys Res Commun.385 ( 2 ) 132 - 136   2009.1Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Kawahara K, Hashiguchi T, Masuda K, Saniabadi AR, Kikuchi K, Tancharoen S, Ito T, Miura N, Morimoto Y, Biswas KK, Nawa Y, Meng X, Oyama Y, Takenouchi K, Shrestha B, Sameshima H, Shimizu T, Adachi T, Adachi M, Maruyama I. .  Mechanism of HMGB1 release inhibition from RAW264.7 cells by oleanolic acid in Prunus mume Sieb. et Zucc. .  nt J Mol Med.23 ( 5 ) 615 - 620   2009.1Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Kawahara K, Biswas KK, Unoshima M, Ito T, Kikuchi K, Morimoto Y, Iwata M, Tancharoen S, Oyama Y, Takenouchi K, Nawa Y, Arimura N, Jie MX, Shrestha B, Miura N, Shimizu T, Mera K, Arimura S, Taniguchi N, Iwasaka H, Takao S, Hashiguchi T, Maruyama I. .  C-reactive protein induces high-mobility group box-1 protein release through activation of p38MAPK in macrophage RAW264.7 cells. .  Cardiovasc Pathol.17 ( 3 ) 129 - 138   2008.1Reviewed

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Kawahara K, Hashiguchi T, Kikuchi K, Tancharoen S, Miura N, Ito T, Oyama Y, Nawa Y, Biswas KK, Meng X, Morimoto Y, Shrestha B, Sameshima H, Maruyama I. .  Induction of high mobility group box 1 release from serotonin-stimulated human umbilical vein endothelial cells. .  Int J Mol Med. 22 ( 5 ) 639 - 644   2008.1Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Kawahara K, Tancharoen S, Hashiguchi T, Unoshima M, Ito T, Kikuchi K, Morimoto Y, Shimizu T, Oyama Y, Takenouchi K, Arimura S, Taniguchi N, Iwata M, Iwasaka H, Maruyama I. .  Inhibition of HMGB1 by deep ocean water attenuates endotoxin-induced sepsis. .  Med Hypotheses.68 ( 6 ) 1429 - 1430   2007.1Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

▼display all

Books

  • ELISA、マルチプレックス

    大山陽子、橋口照人（ Role： Joint author）

    呼吸  2013.10 

    　More details

    Language：Japanese Book type：Scholarly book

  • 高フィブリノゲン血症

    大山陽子、橋口照人（ Role： Joint author）

    別冊日本臨牀 血液症候群(第2版)  2013.5 

    　More details

    Language：Japanese Book type：Scholarly book

  • HMGB1とRAGEシグナル 生体侵襲と臓器管理 －急性期病態の理解とその対応－

    大山陽子、丸山征郎（ Role： Joint author）

    救急・集中治療 総合医学社  2008.1 

    　More details

    Language：Japanese Book type：Scholarly book

  • 色調異常：血液、症状からみた血管疾患事典 血管疾患の鑑別診断

    大山陽子、丸山征郎（ Role： Joint author）

    Vascular Laboratory・メディカ出版  2006.1 

    　More details

    Language：Japanese Book type：Scholarly book

  • 緊急検査と評価

    大山陽子、橋口照人、丸山征郎（ Role： Joint author）

    診断と治療 増刊号:救急医療  2003.1 

    　More details

    Language：Japanese Book type：Scholarly book

Presentations

  • 大山陽子、竹之内和則、舞木公子、郡山豊泰、福山竜子、川畑恵、古城剛、山口宗一、政元いずみ、橋口照人   24時間体制で血液培養陽性検体のサブカルチャーを可能にしたことによる患者アウトカムの検討  

    第65回日本臨床検査医学会学術集会  第65回日本臨床検査医学会学術集会

    　More details

    Event date： 2018

    Venue：東京  

  • 大山陽子、竹之内和則、古城剛、郡山豊泰、福山竜子、川畑恵、山口宗一、橋口照人   血液培養陽性データよりみる真菌検出菌とその臨床背景  

    第64回日本臨床検査医学会学術集会  第64回日本臨床検査医学会学術集会

    　More details

    Event date： 2017

    Venue：京都  

  • 大山陽子、竹之内和則、古城剛、郡山豊泰、福山竜子、山口宗一、橋口照人   血液培養陽性データよりみる検出菌とその臨床背景  

    第63回日本臨床検査医学会学術集会  第63回日本臨床検査医学会学術集会

    　More details

    Event date： 2016

    Venue：神戸  

  • Chinese herbal medicine "Wu Ling San" had anti-oxidant activity in crystal induced granulomatous nephritis in rats.  

    7th International Symposium DAMPS and HMGB1 

    　More details

    Event date： 2015

    Language：English   Presentation type：Poster presentation  

    Venue：Bonn   Country：Germany  

  • 大山陽子   漢方薬は自然炎症制御薬となりうるか？～DAMPsコントローラーとしての漢方～  

    第65回日本東洋医学会学術集会 シンポジウム「東洋医学の発想と近代医学の最前線：未病と自然炎症」  第65回日本東洋医学会学術集会 シンポジウム「東洋医学の発想と近代医学の最前線：未病と自然炎症」

    　More details

    Event date： 2014.6

    Language：Japanese  

    Venue：東京  

    国内学会

  • 大山陽子、竹之内和則、郡山豊泰、山口宗一、橋口照人   病態解析情報を含む感染症データベースシステムの構築  

    第61回日本臨床検査医学会学術集会  第61回日本臨床検査医学会学術集会

    　More details

    Event date： 2014

    Venue：福岡  

  • 大山陽子   漢方薬は自然炎症制御薬となりうるか？～自然炎症腎炎モデルを用いた検証～  

    第64回日本東洋医学会学術集会 シンポジウム「免疫と漢方－関節リウマチを題材に融合治療を考える」  第64回日本東洋医学会学術集会 シンポジウム「免疫と漢方－関節リウマチを題材に融合治療を考える」

    　More details

    Event date： 2013.6

    Language：Japanese  

    Venue：鹿児島  

    国内学会

  • Yoko Oyama, Teruto Hashiguchi, Noboru Taniguchi, Salunya Tancharoen, Yuko Nawa, Tomonori Uchimura, Kamal K. Biswas, Ko-ichi Kawahara, Takao Nitanda, Yoshihisa Umekita, Martin Lotz, Ikuro Maruyama   High-mobility group box-1 protein promotes Granulomatous nephritis in a cycle involving monocyte chemoattractant protein - 1   International conference

    ESF- JSPS Frontier Science Conference for Young Researchers  ESF- JSPS Frontier Science Conference for Young Researchers

    　More details

    Event date： 2011.3

    Language：English  

    Venue：Hulshort, The Netherlands  

    国際学会

  • Y. Oyama, T. Hashiguchi, N. Taniguchi, S. Tancharoen, T. Uchimura, K. Biswas, K. Kawahara, T. Nitanda, Y. Umekita, M. Lotz, I. Maruyama.   High-mobility Group Box-1 Protein Promotes Granulomatous Nephritis in Adenine-induced nephropathy.   International conference

    The 18th International Symposium on Molecular Cell Biology of Macrophages 2010.  The 18th International Symposium on Molecular Cell Biology of Macrophages 2010.

    　More details

    Event date： 2010.1

    Language：English  

    Venue：Kumamoto, Japan  

    国際学会

  • Y. Oyama, S. Tancharoen, T. Ito, T. Hashiguchi, T. Uchimura, K. Kawahara, I. Maruyama   Chinese herbal medicine "Wu Ling San" had anti-inflammatory activity in crystal induced nephritis in rats.   International conference

    WorldPharma 2010.  WorldPharma 2010.

    　More details

    Event date： 2010.1

    Language：English  

    Venue：Copenhagen, Denmark.  

    国際学会

  • Y. Oyama, T. Hashiguchi, N. Taniguchi, S. Tancharoen, Y. Nawa, T. Uchimura, K. Biswas, K. Kawahara, T. Nitanda,Y. Umekita, M. Lotz, I. Maruyama   High-mobility group box-1 protein promotes Granulomatous nephritis in adenine-induced nephropathy.   International conference

    The 4th International HMGB1Symposium SIGNALS OF TISSUE DAMAGE.  The 4th International HMGB1Symposium SIGNALS OF TISSUE DAMAGE.

    　More details

    Event date： 2010.1

    Language：English  

    Venue：Helsinki, Finland.  

    国際学会

  • Y. Oyama, T. Hashiguchi, T. Uchimura, S. Tancharoen, K. Biswas, K. Kawahara, Y. Nawa, T. Nitanda, S. Yamada, Y. Umekita, I. Maruyama   High-mobility Group Box-1 Protein Causes Granulomatous Nephritis Formation via a Vicious Cycle with Monocyte Chemoattractant Protein-1 and Tumor Necrosis Factor-a in an Experimental Model.   International conference

    The Third International Damage Associated Molecular Pattern Molecules (DAMPs) and Alarmins Symposium,  The Third International Damage Associated Molecular Pattern Molecules (DAMPs) and Alarmins Symposium,

    　More details

    Event date： 2008.1

    Language：English  

    Venue：Pittsburgh, Pennsylvania, USA.  

    国際学会

  • Y. Oyama, S. Tancharoen, T. Ito, T. Hashiguchi, T. Uchimura, K. Kawahara, I. Maruyama   An Anti-oxidant Capacity of Chinese Herbal Medicine “Wu Ling San” in Experimental Granulomatous Nephritis Model.   International conference

    The Ⅸth World Conference on Clinical Pharmacology and Therapeutics  2008 

    　More details

    Event date： 2008

    Language：English   Presentation type：Poster presentation  

    Country：Canada  

  • 大山陽子、内村友則、川原幸一、Biswas K. Kamal, 橋口照人、小玉拓郎、早田正和、地頭方良江、梅北善久、吉田浩己、塗木千鶴、徳満貴子、二反田隆夫、北島信一、山田晋吾、丸山征郎   結晶誘発腎炎の炎症遷延化はHMGB1とMCP-1の相互放出による悪循環が関与する－ラット腎結石モデルによる検討  

    第24回サイトプロテクション研究会  第24回サイトプロテクション研究会

    　More details

    Event date： 2006.1

    Language：Japanese  

    Venue：京都  

    国内学会

  • Y. Oyama, T. Uchimura, K. Biswas, K. Kawahara, T. Hashiguchi, S. Yamada, I. Maruyama   HMGB1 and MCP-1 cooperatively act as smoldering inflammatory mediators forming vicious cycle. An insight from adenine-induced chronic interstitial nephritis model in rats.   International conference

    EMBO Workshop on Innate Danger Signals and HMGB1  2006 

    　More details

    Event date： 2006

    Language：English   Presentation type：Poster presentation  

    Venue：Milan, Italy   Country：Italy  

  • 中村 政敏, 小濱 祐行, 古城 剛, 野邊 紗耶香, 有村 尚子, 村田 奈穂, 茂見 茜里, 波野 史典, 川村 英樹, 大山 陽子, 橋口 照人, 西 順一郎   鹿児島県における薬剤耐性対策アクションプランに準じた薬剤耐性菌サーベイランスシステムの活用について  

    医療検査と自動化  2024.8  (一社)日本医療検査科学会

    　More details

    Language：Japanese  

  • 川村 英樹, 山口 浩樹, 児玉 祐一, 池田 賢一, 久保田 真吾, 高橋 宜宏, 竹之内 和則, 大山 陽子, 山口 宗一, 大川 大輔, 新山 修平, 垣花 泰之, 橋口 照人   鹿児島県における感染症専門医養成活動  

    日本感染症学会総会・学術講演会・日本化学療法学会学術集会合同学会プログラム・抄録集  2024.5  日本感染症学会・日本化学療法学会

    　More details

    Language：Japanese  

  • 山口 宗一, 上田 英昭, 向原 公介, 松本 和久, 大川 政士, 竹之内 和則, 大山 陽子, 東 貞行, 藤崎 知園子, 井本 浩, 橋口 照人   血管平滑筋細胞石灰化のmiRNA依存性制御機構の検討  

    日本血栓止血学会誌  2021.5  (一社)日本血栓止血学会

    　More details

    Language：Japanese  

  • 山口 宗一, 大川 政士, 竹之内 和則, 東 貞行, 藤崎 知園子, 大山 陽子, 田上 聖徳, 田原 明人, 橋口 照人   血漿中,血小板内のVEGF-A121とVEGF-A165の動態についての検討  

    日本血栓止血学会誌  2024.5  (一社)日本血栓止血学会

    　More details

    Language：Japanese  

  • 東 貞行, 山口 宗一, 大川 政士, 竹之内 和則, 藤崎 知園子, 大山 陽子, 田上 聖徳, 田原 明人, 橋口 照人   血漿、血清中と血小板内のVEGF-Aisoformの検討　VEGF-A121特異的ELISAとVEGF-A165特異的ELISAの開発  

    日本血液学会学術集会  2023.10  (一社)日本血液学会

    　More details

    Language：English  

  • 山口 宗一, 大川 政士, 竹之内 和則, 東 貞行, 藤崎 知園子, 大山 陽子, 田上 聖徳, 田原 明人, 橋口 照人   血漿,血清中と血小板内のVEGF-A121とVEGF-A165の検討　VEGF-Aアイソフォーム特異的ELISAの構築  

    医療検査と自動化  2023.8  (一社)日本医療検査科学会

    　More details

    Language：Japanese  

  • 高橋 宜宏, 川村 英樹, 中村 政敏, 大川 大輔, 今村 智美, 茂見 茜里, 大山 陽子   血液培養ボトル供給制限による診療およびサーベイランスへの影響についての検討  

    日本感染症学会総会・学術講演会・日本化学療法学会学術集会合同学会プログラム・抄録集  2025.4  日本感染症学会・日本化学療法学会

    　More details

    Language：Japanese  

  • 川村 英樹, 池増 鮎美, 西 順一郎, 大山 陽子, 中村 政敏, 松元 優太, 山崎 芳人, 折田 富之   血液培養の推進を目的とした地域ネットワークでのアンケート・パネルディスカッションの取り組み  

    日本化学療法学会雑誌  2024.3  (公社)日本化学療法学会

    　More details

    Language：Japanese  

  • 山口 宗一, 向原 公介, 上田 英昭, 大川 政士, 松本 和久, 竹之内 和則, 大山 陽子, 東 貞行, 藤崎 知園子, 井本 浩, 橋口 照人   血中microRNA-126と血小板VEGF-Aの相互関連性についての検討  

    医療検査と自動化  2021.8  (一社)日本医療検査科学会

    　More details

    Language：Japanese  

  • 郡山 豊泰, 大山 陽子, 川畑 恵, 小濱 祐行, 福山 竜子, 舞木 公子, 中村 政畝, 藤崎 知園子, 東 貞行, 田上 聖徳, 竹之内 和則, 山口 宗一, 政元 いずみ, 橋口 照人   病院検査室におけるM aviumの偽陽性例の検討  

    日本臨床検査医学会誌  2021.10  (一社)日本臨床検査医学会

    　More details

    Language：Japanese  

  • 山口 宗一, 東 裕子, 竹之内 和則, 大山 陽子, 東 貞行, 藤崎 知園子, 金蔵 拓郎, 橋口 照人   好中球性皮膚疾患に関連する血清マイクロRNAの探索  

    臨床化学  2021.10  (一社)日本臨床化学会

    　More details

    Language：Japanese  

  • 田原 明人, 大川 政士, 山口 宗一, 竹之内 和則, 東 貞行, 藤崎 知園子, 大山 陽子, 田上 聖徳, 橋口 照人   大腸癌患者におけるベバシズマブ投与前後における血漿、血清中VEGF-Aアイソフォーム濃度の検討  

    日本臨床検査医学会誌  2024.10  (一社)日本臨床検査医学会

    　More details

    Language：Japanese  

  • 東 貞行, 藤崎 知園子, 郡山 豊泰, 川畑 恵, 小濱 祐行, 福山 竜子, 舞木 公子, 佐藤 香奈子, 中村 政畝, 政元 いずみ, 田上 聖徳, 大山 陽子, 竹之内 和則, 山口 宗一, 橋口 照人   呼吸器糸状菌感染症の簡便な検出率改善への試み  

    日本臨床検査医学会誌  2021.10  (一社)日本臨床検査医学会

    　More details

    Language：Japanese  

  • 竹之内 和則, 山口 宗一, 大川 政士, 東 貞行, 藤崎 知園子, 大山 陽子, 田上 聖徳, 田原 明人, 橋口 照人   健常成人における血漿、血清、血小板中のVEGF-A165とVEGF-A121の比較定量解析  

    臨床化学  2023.10  (一社)日本臨床化学会

    　More details

    Language：Japanese  

  • 山口 宗一, 東 裕子, 竹之内 和則, 大山 陽子, 東 貞行, 藤崎 知園子, 田上 聖徳, 金蔵 拓郎, 橋口 照人   乾癬性関節炎における好中球関連マイクロRNAの検討  

    日本血栓止血学会誌  2022.5  (一社)日本血栓止血学会

    　More details

    Language：Japanese  

  • 山口 宗一, 大川 政士, 竹之内 和則, 東 貞行, 大山 陽子, 藤崎 知園子, 田上 聖徳, 田原 明人, 橋口 照人   ベバシズマブ治療による血漿,血清,血小板中のVEGF-A121変化の検討  

    日本検査血液学会雑誌  2024.6  (一社)日本検査血液学会

    　More details

    Language：Japanese  

  • 山口 宗一, 川村 順平, 竹之内 和則, 大山 陽子, 東 貞行, 田原 明人, 田上 聖徳, 藤崎 知園子, 橋口 照人   チアノーゼ性先天性心疾患のグレン手術後の肺動静脈奇形に関連するmiRNAの検討  

    日本臨床検査医学会誌  2024.10  (一社)日本臨床検査医学会

    　More details

    Language：Japanese  

  • 藤崎 知園子, 山口 宗一, 大川 政士, 竹之内 和則, 東 貞行, 田上 聖徳, 田原 明人, 大山 陽子, 橋口 照人   VEGF-A121とVEGF-A165の血漿、血清、血小板中の定量比較解析  

    日本臨床検査医学会誌  2023.10  (一社)日本臨床検査医学会

    　More details

    Language：Japanese  

  • 東 貞行, 藤崎 知園子, 山口 宗一, 竹之内 和則, 大山 陽子, 田上 聖徳, 田原 明人, 橋口 照人   RCPC作成による病態解釈スキルの向上　医学部5,6年生を対象とした教育効果  

    日本臨床検査医学会誌  2023.10  (一社)日本臨床検査医学会

    　More details

    Language：Japanese  

  • 竹之下 友寿, 高手 恵美, 政元 いずみ, 山口 宗一, 竹之内 和則, 大山 陽子, 田上 聖徳, 東 貞行, 藤崎 知園子, 橋口 照人   2種類の凝固促進剤添加採血管を用いた生化学検体安定性の検証  

    臨床化学  2022.9  (一社)日本臨床化学会

    　More details

    Language：Japanese  

▼display all